EUVIMEDEUVIMED entdecken
EditorialOpen Access

AiZynth impact on medicinal chemistry practice at AstraZeneca

Jason D Shields iD, Rachel Howells iD, Gillian Lamont, Yin Leilei, Andrew Madin, Christopher E Reimann, Hadi Rezaei, Tristan Reuillon iD, Bryony Smith, Clare Thomson iD, Yuting Zheng, Robert E Ziegler iD

RSC Medicinal Chemistry · 2024 · 15 (4) · 1085-1095

DOI: 10.1039/d3md00651d ↗

Kurz gefasst

Editorial in der Zeitschrift RSC Medicinal Chemistry, 2024. Verfasst von Jason D Shields und 11 weiteren Autor:innen. Beteiligte Einrichtung: Early Oncology R&D, AstraZeneca 35 Gatehouse Drive Waltham MA 02451 USA jason.shields@astrazeneca.com. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The AI retrosynthesis tool AiZynth has made positive impacts on AstraZeneca drug discovery projects. This opinion provides some examples and discusses how AI retrosynthesis fits into pharmaceutical research.

Autor:innen und Institutionen

  • Early Oncology R&D, AstraZeneca 35 Gatehouse Drive Waltham MA 02451 USA jason.shields@astrazeneca.com.
  • Early Oncology R&D, AstraZeneca 1 Francis Crick Avenue Cambridge CB2 0AA UK.
  • Pharmaron Beijing Co., Ltd. 6 Taihe Road BDA Beijing 100176 P.R. China.
  • Discovery Sciences, AstraZeneca 1 Francis Crick Avenue Cambridge CB2 0AA UK.
  • Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca Pepparedsleden 1 43183 Mölndal Sweden.

ORCID-Profile: Jason D Shields, Rachel Howells, Tristan Reuillon, Clare Thomson, Robert E Ziegler

Zitieren

APA

Shields, J. D., Howells, R., Lamont, G., Leilei, Y., Madin, A., Reimann, C. E., Rezaei, H., Reuillon, T., Smith, B., Thomson, C., Zheng, Y., & Ziegler, R. E. (2024). AiZynth impact on medicinal chemistry practice at AstraZeneca. RSC Medicinal Chemistry, 15(4), 1085-1095. https://doi.org/10.1039/d3md00651d

Vancouver

Shields JD, Howells R, Lamont G, Leilei Y, Madin A, Reimann CE, et al. AiZynth impact on medicinal chemistry practice at AstraZeneca. RSC Medicinal Chemistry. 2024;15(4):1085-1095. doi:10.1039/d3md00651d

BibTeX
@article{Shields2024,
  author = {Shields, Jason D and Howells, Rachel and Lamont, Gillian and Leilei, Yin and Madin, Andrew and Reimann, Christopher E and Rezaei, Hadi and Reuillon, Tristan and Smith, Bryony and Thomson, Clare and Zheng, Yuting and Ziegler, Robert E},
  title = {AiZynth impact on medicinal chemistry practice at AstraZeneca},
  journal = {RSC Medicinal Chemistry},
  year = {2024},
  volume = {15},
  number = {4},
  pages = {1085--1095},
  doi = {10.1039/d3md00651d}
}
Kostenlos starten →